Table 5.

HR for combined endpoint of all-cause mortality and ESRD among people with CKD

Clinical CharacteristicUnadjustedAdjusted
HR95% CIPHR95% CIP
Total leukocyte count increase > 11.5 K/μl1.63(1.16, 2.28)<0.011.15(0.80, 1.67)>0.1
Absolute granulocyte count increase > 8.6 K/μl1.7(1.20, 2.40)<0.011.18(0.82, 1.71)>0.1
Absolute eosinophil count increase > 0.45 K/μl2.16(1.54, 3.03)<0.0011.49(1.02, 2.17)0.04
Granulocyte (%) increase > 70%2.99(2.01, 4.44)<0.0011.75(1.14, 2.68)0.01
Lymphocyte (%) decrease < 18%1.52(1.05, 2.21)0.030.91(0.61, 1.36)>0.1
Monocyte (%) increase > 11%2.93(2.01, 4.27)<0.0011.76(1.17, 2.64)<0.01
Eosinophil (%) increase > 3%1.94(1.41, 2.67)<0.0011.58(1.13, 2.22)<0.01
Basophil (%) increase > 2%1.38(0.98, 1.96)0.071.42(0.98, 2.06)0.06
  • Multivariate adjusted for age, gender, race, diabetes, smoking, ACEI or ARB use, statin use, BP medication use, baseline CKD stage, and baseline log urine protein/creatinine. HR, hazard ratio; CI, confidence interval.